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Background: Aberrant promoter CpG island hypermethylation is associated with transcriptional silencing. Tumor
suppressor genes are the key targets of hypermethylation in breast cancer and therefore may lead to malignancy
by deregulation of cell growth and division. Our previous pilot study with pairs of malignant and normal breast
tissues identified correlated methylation of two pairs of genes - HIN-1/RASSFIA and RIL/CDH13 - with expression of
estrogen receptors (ER), progesterone receptors (PR), and HER2 (HER2). To determine the impact of methylation on
clinical outcome, we have conducted a larger study with breast cancers for which time to first recurrence and
overall survival are known.
Methods: Tumors from 193 patients with early stage breast cancer who received no adjuvant systemic therapy
were used to analyze methylation levels of RIL, HIN-1, RASSF1A and CDH13 genes for associations with known
predictive and prognostic factors and for impact on time to first recurrence and overall survival.
Results: In this study, we found that ER was associated with RASSF1A methylation (p< 0.001) and HIN-1
methylation (p= 0.002). PR was associated with RIL methylation (p= 0.012), HIN-1 (p= 0.002), and RASSF1A
methylation (p= 0.019). Tumor size was associated with RIL and CDH13 methylation (both p= 0.002), and S-phase
was associated with RIL methylation (p= 0.036). Only RASSF1A was associated with worse time to first recurrence
(p= 0.045) and worse overall survival (p= 0.016) after adjusting for age, tumor size, S-phase, estrogen receptor and
progesterone receptor.
Conclusions: Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancers was associated with clinical
characteristics, but only RASSF1A methylation was associated with time to first recurrence and overall survival. Our
data suggest that RASSF1A methylation could be a potential prognostic biomarker.* Correspondence: sgh@bcm.edu; yinhuay@gmail.com
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Breast cancer is the leading cause of cancer-related death
in women worldwide, but the exact etiology of breast can-
cer remains elusive. DNA methylation has attracted inten-
sive investigation in recent years and it is thought to play
an important role in the regulation of genes related to
cancer [1]. Several tumor suppressor genes are silenced by
promoter hypermethylation in breast cancers including
HIN-1 [2], RASSF1A [3], RIL [4], and CDH13 [5], among
others. Aberrant DNA methylation of particular genes has
been correlated with the clinical and pathologic character-
istics of breast cancers and with clinical outcomes [6].
It is widely recognized that subtypes identified through
gene expression profiling are associated with distinct
clinical outcomes and targets for treatment [7-10]. DNA
methylation markers have been applied as an alternative
approach to molecular profiling of breast cancer
[5,6,11]. CDH13 has been reported to be highly methy-
lated in HER2/neu-positive breast cancers, which com-
prise 20% to 30% of invasive breast carcinomas.
Methylated CDH13 is associated with increased meta-
static potential and lower tamoxifen sensitivity [11].
Higher methylation of HIN-1 has been found in bone,
brain, and lung metastases compared to the associated
primary breast carcinomas [12]. RASSF1A promoter
methylation provides important prognostic information
in early stage breast cancer patients [13]. All of these
results suggest that DNA methylation profiling corre-
lates with clinical status in breast cancer and could help
predict response to hormonal and non-hormonal breast
cancer therapy [5]. However, a persistent panel of DNA
methylation markers which are correlated with clinic
characteristics and outcomes in breast cancers has not
been described in detail yet.
To investigate the associations between gene methylation
profiles and hormone receptor status in patient samples,
our previous study measured methylation of 12 known
tumor-suppressor genes in 90 pairs of breast cancers and
normal tissues, and we found that five genes proved useful
in defining a methylation profile in breast cancer cells. We
also found that two panels of methylation profiles (HIN-1/
RASSF1A, and RIL/CDH13) correlated, either positively or
negatively, with estrogen receptors (ER), progesterone
receptors (PR) or Her-2-neu status [6]. This observation,
while interesting, is of limited utility due to the small sam-
ple size and lack of outcome data. To confirm our observa-
tion and to determine whether methylation profiles of these
particular genes have prognostic significance, we analyzed
193 well annotated breast cancers.
Methods
Tissue samples
For this study, we used breast cancer tissue samples and
associated clinicopathologic data from the tissue banksat the Lester and Sue Smith Breast Center at Baylor
College of Medicine. All tissue samples were obtained
after receiving informed consent according to institu-
tional rules. No patient was recruited specifically for this
study which was approved by Institutional Review
Boards of The University of Texas M.D. Anderson
Cancer Center and of Baylor College of Medicine.
Tumor samples from 193 patients were obtained from
the excess tissue collected during medically necessary
procedures to excise primary breast cancers between
1973 and 1999. The tissue was flash-frozen and pulver-
ized for steroid receptor assessment by ligand binding
assay in one of two central laboratories. The remainder
was kept for future research. This tissue resource was
aliquoted and stored at −80 °C in cryovials. In June
2001, the area where these samples were stored was
flooded, and samples thawed and were then refrozen 48
hours later. Although proteins and mRNA were
degraded, moderate length DNA remained intact, and is
useful for a variety of DNA based assays. The tissue
banks which contributed tumor samples toward this
study have been continuously approved since inception
by relevant institutional review boards. None of the
patients who provided the tumor samples chosen for this
study was given adjuvant therapy.
Prognostic factors
ER levels were measured by the dextran-coated charcoal
method, as previously described [14]. From 1970 to
1984, [3H] estradiol was used as the labeled ligand. Dur-
ing the same period, PR levels were measured by sucrose
density gradient [15]. In 1985, the standard multipoint
dextran-coated charcoal assay was modified to incorpor-
ate [125I] estradiol and [3H] R5020 in a single assay,
allowing the simultaneous determination of both ER and
PR. Samples containing at least 3 fmol/mg protein were
considered ER positive, and those containing at least
5 fmol/mg protein were considered PR positive, based
on prior clinical studies [16-18].
DNA ploidy and S-phase fraction were evaluated by
flow cytometry and the histograms were analyzed by
Modfit (Verify Software House, Topsham, ME) using
singlecut debris stripping [18]. Cutpoints were deter-
mined by calibrating S-phase fraction with clinical out-
come in a group of more than 28,800 patients with
breast cancer (low, <6%; intermediate, 6%–10%; high
> 10%) [19].
DNA extraction and sodium bisulfite treatment
In brief, genomic DNA was extracted from patient sam-
ples, breast cancer cell lines, and normal breast epithelial
cells using the Dneasy tissue kit (Qiagen, Valencia, CA,
USA). Bisulfite treatment of 1–2 μg of genomic DNA
was performed, as previously described [20].
Table 1 Characteristics of subjects in the dataset (N=193)













Infiltrating Papillary 2 (1.04%)
Adenocarcinoma 2 (1.04%)
Carcinoma, NOS 2 (1.04%)
Tumor Size
≤ 2 cm 97 (50.26%)
>2 cm and ≤ 5 cm 96 (49.74%)
Stage
Stage I 97 (50.26%)











Low-Medium (≤10%) 102 (53.13%)
High (> 10%) 90 (46.88%)
RIL 18.1% (0, 91.2)
HIN-1 13.6% (0, 98.4)
RASSF1A 16.1% (0, 97.1)
CDH13 8.6% (0, 77.1)
Age 62 years (30, 88)
Median follow-up time* 152 months
*Determined by scoring deaths as censored events and calculating follow-up
time using Cox regression.
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Four tumor-suppressor genes, RASSF1A, SCGB3A1
(HIN-1), PDLIM4 (RIL) and CDH13 were selected for
this study. Pyrosequencing methylation analysis was
used to detect methylation of all 4 genes. Pyrosequen-
cing primers were designed using Assay Design software
1.0 (Biotage, Westborough, MA, USA). For each gene,
we selected the CpG island region flanking the transcrip-
tion start site at the 5'UTR. Two to six CpG sites were
studied for each particular CpG island. The primers for
pyrosequencing and PCR conditions are the same as
previously reported [6]. Bisulfite-treated DNA (1 μl) was
amplified in 50 μl of reaction mixture, containing pri-
mers and 0.2 U of Taq polymerase (New England
Biolabs, Ipswich, MA, USA). For the amplification of
HIN-1, we used a universal primer approach [6]. The
PCR product was purified and methylation was quanti-
tated using the PSQ HS 96A pyrosequencing system and
Pyro gold reagents (Biotage). Methylation data are pre-
sented as the average percentage of methylation in all
observed CpG sites. To set the controls for pyrosequen-
cing, we used cancer cell lines and normal cells that
were consistently positive or negative with stable levels
of methylation. In this study, each PCR assay included a
positive control (the MDA-MB-231 breast cancer cell
line, which is highly methylated in most genes) and a
negative control (normal breast epithelial cells,
HMEC231, which are unmethylated in all genes).
Statistical methods and analysis
Subject and tumor characteristics were summarized in the
193 subjects with methylation data using descriptive sta-
tistics. The methylation values (expressed as the average
percentage methylation of all CpG sites for a particular
gene) ranged from 0 to 98% and were highly skewed. Dif-
ferences in methylation levels as a function of tumor char-
acteristics were analyzed with Wilcoxon rank sum tests,
and these results were reported with adaptive Hochberg
p-values to adjust for multiple comparisons. In addition,
the median methylation level of each gene was reported
for each tumor characteristic group.
For survival analysis, the gene values were divided at
the median with the lower half as the reference group.
Time to first recurrence (TTFR) was calculated from the
diagnostic biopsy date to first recurrence. Subjects with-
out an event were censored at the time of death (other
causes) or last follow-up. Overall survival (OS) was cal-
culated from the diagnostic biopsy date to death, censor-
ing subjects who were alive at the time of last follow-up.
For each gene, the effect of methylation on time to first
recurrence and on overall survival was examined using
Kaplan-Meier curves and differences in survival were
evaluated with the log-rank test. Where the log-rank test
was significant at α= 0.05, Cox regression was used tomodel the relationship, and hazards ratios and 95% con-
fidence intervals were calculated for the univariable and
multivariable models. The proportional hazards assump-
tion was checked with graphical and time-varying
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cluded investigation of subgroups. All analyses were per-
formed using SAS 9.2 (SAS, Cary, NC) and R software,
version 2.10.1.
Results
Characteristics of the patients and breast cancers
Tumors from 193 patients with early stage breast cancer
who received no adjuvant systemic therapy were used
for analysis. The patients’ clinical characteristics were
summarized in Table 1. Most of the subjects were Cau-
casian (74.86%) and post-menopausal (84.44%). Of the
193 patients, 161 cases (83.42%) were initially diagnosed
as Infiltrating Ductal Carcinomas, the majority were
ER + (141, 73.06%) and aneuploid (113, 58.55%) and had
low-medium S-phase (102, 53.13%). Eighty-five cases
(47.49%) were PR+. The median follow-up time was































CDH13 7.10%Association of methylation with clinical characteristics
The median values for methylation of the four genes
ranged from 8.6% to 18.1% (Table 1). White subjects and
non-White subjects had similar methylation levels for
the genes and there was no statistically-significant differ-
ence in the methylation levels of the genes by race group
(data not shown). In addition, we found that methylation
values appear to differ by different tumor characteristics.
Higher median methylation values were seen for all four
genes with larger tumor-size (T2, 2–5 cm) than with
smaller tumor-size, (T1,< 2 cm) and with aneuploid
compared to the diploid cancers (data not shown).
Associations between the patients’ clinical characteris-
tics and methylation of the four genes were evaluated
using Wilcoxon rank sum test with adaptive Hochberg p-
values to adjust for multiple comparisons (Table 2). ER+
tumors had higher median methylation levels of HIN-1
(p= 0.002), and RASSF1A (p< 0.001), and PR+ tumorsultiple comparisons for gene methylation levels and
Level Adaptive Hochberg p-value for


























Figure 1 Time to First Recurrence by RASSF1A methylation
status.
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(p=0.019). Lower levels of RIL (p= 0.012) were also found
in PR+ tumors. Smaller tumors (≤ 2 cm) had lower
methylation levels of all four genes, and methylation of
RIL and CDH13 (both p=0.0020) differed significantly by
tumor size group. Lower methylation levels of RIL were
found in tumors with low S-phase (p= 0.036) and in dip-
loid tumors (p< 0.001).
Association between methylation of genes and patient
survival
As the median follow-up time for the dataset was
152 months, we were interested in seeing if methylation
of the four tumor suppressor genes was associated with
patient survival or time to first recurrence. We found
that higher methylation of RASSF1A was associated with
worse time to first recurrence {HR= 1.93, 95% CI (1.02,
3.67), p= 0.045} and worse overall survival {HR= 1.74,
95% CI (1.11, 2.74), p= 0.016} in multivariable models
that included age, tumor size, S-phase, ER, and PR
(Table 3, Figures 1 and 2). In a breast cancer-specific
multivariable model, RASSF1A was not associated with
worse breast-cancer specific survival {HR= 0.86, 95% CI
(0.36, 2.06); p= 0.73}. Substantial violations of propor-
tional hazards were not found in these comparisons, and
there is no expectation that the conclusions were
affected. Collectively, these results suggest that overall
survival may have been associated with other factors that
were potentially confounding factors, including lack of
adjuvant therapy and the time period in which these
cases were collected.
Discussion
It is evident that methylation plays an important role in
breast cancer development and progression. Hypomethy-
lation of DNA may lead to chromosomal instability, while
aberrant promoter CpG island hypermethylation is asso-
ciated with transcriptional silencing. Tumor suppressorTable 3 Multivariable Survival Analysis Results by median
methylation level (< median is the reference group)
Gene Outcome HR (95% CI) p-value*
RIL TTFR 1.53 (0.85, 2.77) 0.16
OS 1.12 (0.76, 1.67) 0.57
HIN-1 TTFR 1.49 (0.83, 2.68) 0.19
OS 1.21 (0.82, 1.80) 0.34
RASSF1A TTFR 1.93 (1.02, 3.67) 0.045
OS 1.74 (1.11, 2.74) 0.016
CDH13 TTFR 0.75 (0.42, 1.33) 0.32
OS 1.15 (0.77, 1.70) 0.50
The models include age (continuous), tumor size (continuous), S-phase, ER
(continuous) and PR (continuous).
*P-value from Cox regression model.genes, such as RASSF1A, HIN-1, are the key targets of
hypermethylation in breast cancer and therefore may
lead to malignancy by deregulation of cell and growth
cycles. Although there have been numerous studies of
methylation in breast tumors associations between the
methylation of tumor suppressor genes with clinical
characteristics and outcome, a substantial limitation of
these different studies is that the data are highly variable,
possibly due to differences in laboratory and statistical
methods, sample size and clinical status of the subjects.
Our previous report showed that methylation of 4
tumor suppressor genes (RASSF1A, HIN-1, RIL and
CDH13) correlate with hormone receptor status [6]. TheFigure 2 Overall Survival by RASSF1A methylation status.
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study with a larger, independent sample. In this study, we
found that ER and PR were associated with RASSF1A and
HIN-1; PR was also associated with RIL. We have also
found that RIL methylation levels significantly differed by
tumor size, S-phase and ploidy groups. CDH13 methyla-
tion levels significantly differed by tumor size group.
These data are consistent with our previous findings that
RASSF1A/HIN-1 were associated with hormone status; in
addition, we have shown that RIL and CDH13 were asso-
ciated with tumor characteristics.
This project also gave us the opportunity to examine
the association between promoter methylation of the
four tumor suppressor genes and prognosis. We found
that hyper-methylated RASSF1A was associated with
worse overall survival and worse time to first recurrence.
The results from the survival analyses suggest that over-
all survival may have been associated with other factors,
including lack of adjuvant therapy and the time period
in which these cases were collected.
RASSF1A is a well studied tumor suppressor gene,
which plays important role in many cell functions: apop-
tosis, cell cycle arrest, microtubule stabilization and
metaphase arrest [21,22]. Re-expression of RASSF1A in
tumor cell lines decreases in vitro colony formation and
in vivo tumorigenicity [21]. DNA methylation of
RASSF1A would be expected to lead to loss of function
and an increase in spontaneous or induced tumor for-
mation. Our data combined with other groups’ data sug-
gest that RASSF1A methylation could be a potential
molecular biomarker, and further replication analyses in
larger cohorts and different populations are warranted.
Although the results from this study indicate that the
methylation of RASSF1A may be associated with overall
survival, it is possible that these findings may be affected
by unmeasured potentially confounding factors. It is also
feasible that these results are due to chance, as different
methylation levels were used to define hyper-
methylation for each gene and the only positive results
were found for RASSF1A.Conclusions
Tumors from 193 patients with early stage breast cancer
were used to analyze promoter methylation of the RIL,
HIN-1, RASSF1A and CDH13 tumor suppressor genes
for association with known predictive and prognostic fac-
tors and for impact on time to first recurrence and overall
survival. Methylation of HIN-1, RASSF1A, RIL and
CDH13 were associated with a number of different clinical
characteristics, but only hyper-methylated RASSF1A was
associated with worse overall survival and worse time to
first recurrence. These results and those of other groups
suggest that further studies are reasonable to determine ifRASSF1A methylation could be a potential prognostic
biomarker.
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